Weekly Recap. April 8-12, 2019


12-Apr-2019 17:22 PM



In case you missed this past week market movers news.

Monday Dow Jones -83.97%,  QQQ +0.25%, IWM-0.17%, IBB -0.43%, SPY +0.08%

  • New Age Beverages (NBEV) stock rallies +37.03% distribution expansion with Walmart
  • Roku Inc (ROKU) Citi downgrades to sell, PT $50
  • Micron Technology Inc (MU) downgrades to Market Perform at Cowen, PT $45
  • Snap Inc (SNAP) upgrades to Outperform, PT $17


  • PhaseBio Pharmaceuticals Inc (PHAS)- Breakthrough Therapy Designation from the FDA
  • Zogenix Inc (ZGNX)- get Refusal to file letter from FDA for seizure drug

Wednesday Dow Jones finished the day up +6.58 point, SPY 0.34%, QQQ +0.54%, IWM +1.36%, IBB +1.10%

  • Lyft Inc (LYFT) stock down -10.85% to $60.12 ahead of Uber IPO
  • First Solar Inc (FSLR) Goldman Sach added to Conviction Buy list.
  • Apple Inc (AAPL) HSBC downgrades to Reduce, PT $180

Thursday Dow Jones -14.11 points, SPY -0.03%, QQQ -0.24%, IWM -0.13%, IBB -1.70%

  • Intercept Pharmaceuticals Inc (ICPT) clinical data update, highlights Positive data from REGENERATE, the First successful Phase 3 study in NASH. Stock down -13.20$ to $104.75
  • Viking Therapeutics Inc (VKTX) New data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD). Stock end in red after sell-the-news. Down -1.58%
  • Weight Watchers International (WTW) J.P. Morgan cut it price target by $2 to $12 per share and underweight rating.

Friday +269.25 point, SPY +0.68%, QQQ +0.43%, IWM +0.36%, IBB -0.76%

  • Netflix Inc (NFLX) shares fall to concerns that Disney (DIS) could steal market share by undercutting on price. Stock down -4.49% to $351.14
  • Walt Disney Co (DIS) Disney plus streaming service is Unveiled to Hollywood Fanfare via NYT. Stock up +11.54%
  • PG&E Corp (PCG) Gov Gavin Newsome released a report that suggested that the fires shouldn't be blamed solely on the company, but rather among multiples stakeholders. Stock up +20.65% to $23.08
  • Clovis Oncology Inc (CLVS) discontinuing metastatic bladder cancer PII study. 

Contact us:

Twitter: @BiotechMoney18


Add Your Comment

Please select phase first
Disclaimer! This is NOT an investment advice. The data result herein is purely speculation only. You must do your own due diligence and mitigate your risk. You acknowledge that will not be held responsible and accountable for any losses you may incur using our Biotech Data Calculator. Please consult your own financial adviser before executing trades.